Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 4996 AL 5010

Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease

Lu J, Xu Y, Quan Z, Chen Z, Sun Z, Qing H.

Neuroscience. 2017 Dec 4;365:70-82. doi: 10.1016/j.neuroscience.2017.09.033. Epub 2017 Sep 28.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

Transcranial sonography in psychiatry as a potential tool in diagnosis and research

Drepper C, Geißler J, Pastura G, Yilmaz R, Berg D, Romanos M, Gerlach M.

World J Biol Psychiatry. 2018 Oct;19(7):484-496. doi: 10.1080/15622975.2017.1386325. Epub 2017 Oct 30.

Cognitive changes in prodromal Parkinson's disease: A review

Fengler S, Liepelt-Scarfone I, Brockmann K, Schäffer E, Berg D, Kalbe E.

Mov Disord. 2017 Dec;32(12):1655-1666. doi: 10.1002/mds.27135. Epub 2017 Oct 5.

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort

Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, Tanner CM, Jennings D, Kieburtz K, Chahine LM, Marek K.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):78-88. doi: 10.1136/jnnp-2017-316213. Epub 2017 Oct 6.

Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease

Kaur K, Gill JS, Bansal PK, Deshmukh R.

J Neurol Sci. 2017 Oct 15;381:308-314. doi: 10.1016/j.jns.2017.08.3251. Epub 2017 Aug 26.

The BSSG rat model of Parkinson's disease: progressing towards a valid, predictive model of disease

Van Kampen JM, Robertson HA.

EPMA J. 2017 Sep 4;8(3):261-271. doi: 10.1007/s13167-017-0114-6. eCollection 2017 Sep.

Long-term effects of exercise and physical therapy in people with Parkinson disease

Mak MK, Wong-Yu IS, Shen X, Chung CL.

Nat Rev Neurol. 2017 Nov;13(11):689-703. doi: 10.1038/nrneurol.2017.128. Epub 2017 Oct 13.

Clinical Ethics in the Context of Deep Brain Stimulation for Movement Disorders

Kubu CS, Ford PJ.

Arch Clin Neuropsychol. 2017 Nov 1;32(7):829-839. doi: 10.1093/arclin/acx088.

Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P; GLORIA study co-investigators.

Parkinsonism Relat Disord. 2017 Dec;45:13-20. doi: 10.1016/j.parkreldis.2017.09.018. Epub 2017 Sep 22.

Does Parkinson's disease start in the gut?

Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, Derkinderen P, Beach TG.

Acta Neuropathol. 2018 Jan;135(1):1-12. doi: 10.1007/s00401-017-1777-8. Epub 2017 Oct 16.

Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease

Stojkovska I, Krainc D, Mazzulli JR.

Cell Tissue Res. 2018 Jul;373(1):51-60. doi: 10.1007/s00441-017-2704-y. Epub 2017 Oct 24.

Falls in Parkinson's disease: A complex and evolving picture

Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L.

Mov Disord. 2017 Nov;32(11):1524-1536. doi: 10.1002/mds.27195. Epub 2017 Oct 25.

Cognitive and Neuropsychiatric Features of Early Parkinson's Disease

Getz SJ, Levin B.

Arch Clin Neuropsychol. 2017 Nov 1;32(7):769-785. doi: 10.1093/arclin/acx091.

Structural abnormality of substantia nigra induced by methamphetamine abuse

Rumpf JJ, Albers J, Fricke C, Mueller W, Classen J.

Mov Disord. 2017 Dec;32(12):1784-1788. doi: 10.1002/mds.27205. Epub 2017 Oct 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias